blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4223293

EP4223293 - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER [Right-click to bookmark this link]
Former [2023/32]PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER
[2026/08]
StatusGrant of patent is intended
Status updated on  05.02.2026
Database last updated on 10.03.2026
FormerRequest for examination was made
Status updated on  07.07.2023
FormerThe international publication has been made
Status updated on  08.04.2022
Most recent event   Tooltip05.02.2026New entry: Communication of intention to grant a patent 
Applicant(s)For all designated states
Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
35-2, Sakae-cho
Itabashi-ku
Tokyo 173-0015 / JP
[2023/32]
Inventor(s)01 / INOUE Satoshi
Tokyo 173-0015 / JP
02 / TAKAYAMA Ken-ichi
Tokyo 173-0015 / JP
03 / OSADA Hiroyuki
Wako-shi, Saitama 351-0198 / JP
04 / KONDOH Yasumitsu
Wako-shi, Saitama 351-0198 / JP
 [2023/32]
Representative(s)Gille Hrabal Partnerschaftsgesellschaft mbB Patentanwälte
Brucknerstraße 20
40593 Düsseldorf / DE
[2023/32]
Application number, filing date21874791.320.04.2021
[2023/32]
WO2021JP15982
Priority number, dateJP2020016574530.09.2020         Original published format: JP 2020165745
[2023/32]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022070483
Date:07.04.2022
Language:JA
[2022/14]
Type: A1 Application with search report 
No.:EP4223293
Date:09.08.2023
Language:EN
[2023/32]
Search report(s)International search report - published on:JP07.04.2022
(Supplementary) European search report - dispatched on:EP27.11.2024
ClassificationIPC:A61K31/37, A61P35/00, A61K31/404, A61K31/405, A61K31/453, A61K31/5383, A61P13/08, A61P15/00, A61K31/352, A61K31/5365
[2026/08]
CPC:
A61P13/08 (EP); A61K31/37 (US); A61K31/352 (EP);
A61K31/404 (EP); A61K31/405 (US); A61K31/453 (EP,US);
A61K31/5365 (EP,US); A61P35/00 (EP,US) (-)
Former IPC [2024/41]A61K31/37, A61K31/404, A61K31/405, A61K31/453, A61K31/5383, A61P13/08, A61P15/00, A61P35/00, A61K31/352, A61K31/5365
Former IPC [2023/32]A61K31/37, A61K31/404, A61K31/405, A61K31/453, A61K31/5383, A61P13/08, A61P15/00, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/32]
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON PROSTATAKREBS[2026/08]
English:PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER[2026/08]
French:COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE[2026/08]
Former [2023/32]PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON PROSTATAKREBS ODER BRUSTKREBS
Former [2023/32]PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER
Former [2023/32]COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE OU DU CANCER DU SEIN
Entry into regional phase20.04.2023Translation filed 
20.04.2023National basic fee paid 
20.04.2023Search fee paid 
20.04.2023Designation fee(s) paid 
20.04.2023Examination fee paid 
Examination procedure20.04.2023Examination requested  [2023/32]
17.06.2025Amendment by applicant (claims and/or description)
17.06.2025Date on which the examining division has become responsible
05.02.2026Communication of intention to grant the patent
Fees paidRenewal fee
20.04.2023Renewal fee patent year 03
26.03.2024Renewal fee patent year 04
24.04.2025Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A] US8853182  (INOUE SATOSHI et al.) [A] 1-2 * claims 1-4 * * the whole document *
 [A] WO2007112051  (UNIV ILLINOIS et al.) [A] 1-2 * claims 5,6,8 * * page 1, line 14 - line 29 * * page 3, line 26 - line 30 * * the whole document *
 [X]   HARADA K ET AL: "Coumarins as novel 17^2-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 20, no. 1, 1 January 2010 (2010-01-01), pages 272 - 275, XP026808821, ISSN: 0960-894X, [retrieved on 20091110] [X] 1 * table 1; compound 3e * * page 272, column l, line 1 - column r, line 4 * * the whole document *
 [A]   KEN-ICHI TAKAYAMA ET AL: "Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 114, no. 39, 11 September 2017 (2017-09-11), pages 10461 - 10466, XP055763981, ISSN: 0027-8424, DOI: 10.1073/pnas.1706076114 [A] 1-2 * abstract * * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.1706076114
International search[A] JP2009062300  (SUMITOMO CHEMICAL CO et al.) [A] 1-4 * entire text *
 [A] US2003087946  (FIRESTONE GARY L et al.) [A] 1-4 * entire text *
 [A] JPH09510689   [A] 1-4 * entire text *
 [A] JP2007536226   [A] 1-4 * entire text *
 [A]   ZHANG KEYUN; DING WEIXIAN; SUN JIE; ZHANG BIN; LU FUJIAO; LAI REN; ZOU YONG; YEDID GABRIEL: "Antioxidant and antitumor activities of 4-arylcoumarins and 4-aryl-3,4-dihydrocoumarins", BIOCHIMIE, MASSON, PARIS, FR, vol. 107, 8 April 2014 (2014-04-08), FR , pages 203 - 210, XP029103927, ISSN: 0300-9084, DOI: 10.1016/j.biochi.2014.03.014 [A] 1-4 * entire text *

DOI:   http://dx.doi.org/10.1016/j.biochi.2014.03.014
 [A]   YANG, L. ET AL.: "Dual functional small molecule fluorescent probes for image-guided estrogen receptor-specific targeting coupled potent antiproliferative potency for breast cancer therapy", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 25, 2017, pages 3531 - 3539, XP085037271, DOI: 10.1016/j.bmc.2017.05.002 [A] 1-4 * entire text *

DOI:   http://dx.doi.org/10.1016/j.bmc.2017.05.002
Examination  TAKAYAMA KEN-ICHI ET AL: "Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth", CANCER RESEARCH, vol. 81, no. 13, 11 May 2021 (2021-05-11), pages 3495 - 3508, XP093349607, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-20-3819 [X] 1 * table 1; compound 3e * * page 272, column l, line 1 - column r, line 4 * * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-20-3819
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.